NICE revises biosimilars guidance to conclude that they do not believe that biosimilars are identica...
Read moreRemap Consulting presents NICE's highly specialised technology methodology to EUCOPE
Read moreUpdates on the latest news on NICE's Value Based Assessment, as well as the approval of ultra-orphan...
Read moreIf spending on Hepatitis C drugs exceeds a certain amount, drug manufacturers will be taxed
Read moreIncluding Sovaldi's $84,000 price, adaptive licence pilots from the EMA and is 2015 a turning point ...
Read moreOur quarterly newsletter shares our perspectives on the latest news, developments and thinking withi...
Read moreHow different perspectives on value and price can impact market access
Read moreThe purpose of the new HTA is to ensure proportional incremental costs and effectiveness, as well as...
Read more